Antitrust

As Tim Thomas takes the helm in Atlanta and Macon, TEGNA splits local operations from ad sales to navigate cord-cutting and complex corporate oversight.

As regulatory scrutiny forces legacy proptech to retreat, a new generation of revenue intelligence is targeting commercial real estate's riskiest phase.

As historic commission settlements and market headwinds disrupt real estate, Long & Foster taps Daniel Dennis to scale its tech-integrated survival strategy.

As UK class action claims soar to an unprecedented £14 billion, a new report reveals mounting tensions between judicial efficiency and economic reality.

MyEyeDr.'s acquisition of 300 optometry clinics from EyeCare Partners reveals the quiet, debt-driven unraveling of private equity's vision care mega-platforms.

As CMS prepares to overhaul Medicare Part D contracting, a diverse coalition of specialty pharmacies is mobilizing data to redefine the industry's future.

A landmark California ruling exposes algorithmic health insurer reimbursements to state antitrust laws, threatening automated pricing models nationwide.

Ruger has abruptly dropped its anti-takeover poison pill. Helen Davis deconstructs the regulatory and strategic forces behind this transatlantic firearms alliance.

A $2.5M Canadian class action settlement exposes the hidden costs of a global auto parts cartel, revealing how supply chain oligopolies inflate vehicle prices.

A routine tender offer extension for a small healthcare operator reveals a larger story of a struggling company, a persistent buyer, and a new regulatory era.

The Competition Bureau has moved to block Nortera's acquisition of Green Giant, arguing the deal would reduce choice and raise prices for Canadian families.

The NAIC's summer summit in Columbus places the city's robust insurance ecosystem at the center of national debates on AI governance, climate risk, and state regulation.

A seventh delay in a massive debt restructuring signals deep trouble for the Paramount-WBD mega-merger, raising questions about its financial and legal viability.

Zillow's Q2 revenue soars 18%, but a deeper look reveals a complex reality: declining user traffic, a GAAP net loss, and a high-stakes antitrust battle.

As Washington escalates its war on Big Tech, advisory firm Keystone poaches the DOJ's top economists, gaining the architects of the government's own playbook.

A Dutch court dismissed Shell’s €1B claim against Clariant, a key win. Yet, with billions more in lawsuits pending, is this a true signal of strength?

A Crown corporation's new flyer service is gutting community newspapers, sparking a crisis that pits public service against profit and threatens local democracy.

Union Pacific's merger with Norfolk Southern hinges on a deal with CN. This isn't just a corporate handshake; it's a strategic gambit that will redefine competition in the Midwest.

Millions of recent homebuyers may be eligible for a cash payment from a new $120M settlement. Here's how to claim your share and why it's just one piece of a larger antitrust battle reshaping the entire industry.

A German court ruling against genomics giant Illumina is more than a legal win for a rival; it's a shockwave hitting the core of biotech innovation and biosecurity.